These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 34570452)
1. DNA Damage Response in Glioblastoma: Mechanism for Treatment Resistance and Emerging Therapeutic Strategies. Bonm A; Kesari S Cancer J; 2021 Sep-Oct 01; 27(5):379-385. PubMed ID: 34570452 [TBL] [Abstract][Full Text] [Related]
2. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs. Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101 [TBL] [Abstract][Full Text] [Related]
3. Establishment of a Novel Temozolomide Resistant Subline of Glioblastoma Multiforme Cells and Comparative Transcriptome Analysis With Parental Cells. Ha HA; Yang JS; Tsai FJ; Li CW; Cheng YD; Li J; Hour MJ; Chiu YJ Anticancer Res; 2021 May; 41(5):2333-2347. PubMed ID: 33952458 [TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of the DNA damage response pathway in glioblastoma. Seol HJ; Yoo HY; Jin J; Joo KM; Kong DS; Yoon SJ; Yang H; Kang W; Lim DH; Park K; Kim JH; Lee JI; Nam DH Oncol Rep; 2011 Aug; 26(2):423-30. PubMed ID: 21617879 [TBL] [Abstract][Full Text] [Related]
5. New insight into targeting the DNA damage response in the treatment of glioblastoma. Zhen T; Sun T; Xiong B; Liu H; Wang L; Chen Y; Sun H Chin J Nat Med; 2024 Oct; 22(10):869-886. PubMed ID: 39428180 [TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways. Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459 [TBL] [Abstract][Full Text] [Related]
7. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089 [TBL] [Abstract][Full Text] [Related]
8. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Al-Ejeh F; Kumar R; Wiegmans A; Lakhani SR; Brown MP; Khanna KK Oncogene; 2010 Nov; 29(46):6085-98. PubMed ID: 20818418 [TBL] [Abstract][Full Text] [Related]
9. DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Squatrito M; Holland EC Cancer Res; 2011 Sep; 71(18):5945-9. PubMed ID: 21917735 [TBL] [Abstract][Full Text] [Related]
10. Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis. Marima R; Hull R; Penny C; Dlamini Z Mutat Res Rev Mutat Res; 2021; 787():108376. PubMed ID: 34083040 [TBL] [Abstract][Full Text] [Related]
11. DNA damage response and repair in the development and treatment of brain tumors. Maleki Dana P; Sadoughi F; Mirzaei H; Asemi Z; Yousefi B Eur J Pharmacol; 2022 Jun; 924():174957. PubMed ID: 35430209 [TBL] [Abstract][Full Text] [Related]
12. DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies. Mirza-Aghazadeh-Attari M; Ostadian C; Saei AA; Mihanfar A; Darband SG; Sadighparvar S; Kaviani M; Samadi Kafil H; Yousefi B; Majidinia M DNA Repair (Amst); 2019 Aug; 80():59-84. PubMed ID: 31279973 [TBL] [Abstract][Full Text] [Related]
13. The promise of DNA damage response inhibitors for the treatment of glioblastoma. Majd NK; Yap TA; Koul D; Balasubramaniyan V; Li X; Khan S; Gandy KS; Yung WKA; de Groot JF Neurooncol Adv; 2021; 3(1):vdab015. PubMed ID: 33738447 [TBL] [Abstract][Full Text] [Related]
14. Roles of RNA-Binding Proteins in DNA Damage Response. Kai M Int J Mol Sci; 2016 Feb; 17(3):310. PubMed ID: 26927092 [TBL] [Abstract][Full Text] [Related]
15. A DNA Repair and Cell-Cycle Gene Expression Signature in Primary and Recurrent Glioblastoma: Prognostic Value and Clinical Implications. Gobin M; Nazarov PV; Warta R; Timmer M; Reifenberger G; Felsberg J; Vallar L; Chalmers AJ; Herold-Mende CC; Goldbrunner R; Niclou SP; Van Dyck E Cancer Res; 2019 Mar; 79(6):1226-1238. PubMed ID: 30674534 [TBL] [Abstract][Full Text] [Related]
16. The DNA damage response during mitosis. Heijink AM; Krajewska M; van Vugt MA Mutat Res; 2013 Oct; 750(1-2):45-55. PubMed ID: 23880065 [TBL] [Abstract][Full Text] [Related]
17. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. Gourley C; BalmaƱa J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911 [TBL] [Abstract][Full Text] [Related]
18. Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma. Rasmussen RD; Gajjar MK; Jensen KE; Hamerlik P Mol Oncol; 2016 May; 10(5):751-63. PubMed ID: 26794465 [TBL] [Abstract][Full Text] [Related]
19. Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins. Maachani UB; Kramp T; Hanson R; Zhao S; Celiku O; Shankavaram U; Colombo R; Caplen NJ; Camphausen K; Tandle A Mol Cancer Res; 2015 May; 13(5):852-62. PubMed ID: 25722303 [TBL] [Abstract][Full Text] [Related]
20. DNA damage response inhibitors: An avenue for TNBC treatment. Jin J; Tao Z; Cao J; Li T; Hu X Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188521. PubMed ID: 33556453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]